Format

Send to

Choose Destination
Oncotarget. 2016 Dec 27;7(52):86290-86299. doi: 10.18632/oncotarget.13382.

A microRNA biomarker panel for the non-invasive detection of bladder cancer.

Author information

1
Nonagen Bioscience Corporation, Jacksonville, FL, USA.
2
Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL, USA.
3
Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL USA.
4
Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA.
5
University of Hawaii Cancer Center, Honolulu, HI USA.
6
Department of Urology, Mayo Clinic, Jacksonville, FL USA.

Abstract

The development of accurate, non-invasive urinary assays for bladder cancer would greatly facilitate the detection and management of a disease that has a high rate of recurrence and progression. In this study, we employed a discovery and validation strategy to identify microRNA signatures that can perform as a non-invasive bladder cancer diagnostic assay. Expression profiling of 754 human microRNAs (TaqMan low density arrays) was performed on naturally voided urine samples from a cohort of 85 subjects of known bladder disease status (27 with active BCa). A panel of 46 microRNAs significantly associated with bladder cancer were subsequently monitored in an independent cohort of 121 subjects (61 with active BCa) using quantitative real-time PCR (RT-PCR). Multivariable modeling identified a 25-target diagnostic signature that predicted the presence of BCa with an estimated sensitivity of 87% at a specificity of 100% (AUC 0.982). With additional validation, the monitoring of a urinary microRNA biomarker panel could facilitate the non-invasive evaluation of patients under investigation for BCa.

KEYWORDS:

bladder cancer; diagnostic biomarkers; microRNA; multiplex; urinalysis

PMID:
27863434
PMCID:
PMC5349914
DOI:
10.18632/oncotarget.13382
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center